Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen G Mainz

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
BMC Pulmonary Medicine|June 3, 2014
Dynamics of soluble and cellular inflammatory markers in nasal lavage obtained from cystic fibrosis patients during intravenous antibiotic treatmentJulia Hentschel, Manuela Jäger, Natalie Beiersdorf, et al.
Clinical Chemistry and Laboratory Medicine|April 7, 2021
Audit of sweat chloride testing reveals analytical errorsFreerk Prenzel, Uta Ceglarek, Ines Adams, et al.
NIHR Open Research|August 14, 2024
A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes: a pilot studyChristabella Ng, Neele S Dellschaft, Caroline Hoad, et al.
Frontiers in Pharmacology|May 19, 2023
Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-ScoreJochen G Mainz, Carlos Zagoya, Louise Polte, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 23, 2025
Validation of the CFAbd-Score.kid©, a Novel gastrointestinal patient reported outcome measure, specific for children with cystic fibrosisPauline Sadrieh, Lilith Bechinger, Franziska Duckstein, et al.
Frontiers in Pharmacology|June 20, 2022
Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-ScoreJochen G Mainz, Carlos Zagoya, Louise Polte, et al.
American Journal of Respiratory and Critical Care Medicine|April 18, 2013
Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutationJane C Davies, Claire E Wainwright, Gerard J Canny, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 9, 2016
Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trialJochen G Mainz, Ulrike Schumacher, Katja Schädlich, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 21, 2020
Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance ImagingChristabella Ng, Neele S Dellschaft, Caroline L Hoad, et al.
Microbiology Spectrum|March 9, 2023
The Cystic Fibrosis Upper and Lower Airway MetagenomeKatarzyna Pienkowska, Marie-Madlen Pust, Margaux Gessner, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
BMC Pulmonary Medicine|June 3, 2014
Dynamics of soluble and cellular inflammatory markers in nasal lavage obtained from cystic fibrosis patients during intravenous antibiotic treatmentJulia Hentschel, Manuela Jäger, Natalie Beiersdorf, et al.
Clinical Chemistry and Laboratory Medicine|April 7, 2021
Audit of sweat chloride testing reveals analytical errorsFreerk Prenzel, Uta Ceglarek, Ines Adams, et al.
NIHR Open Research|August 14, 2024
A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes: a pilot studyChristabella Ng, Neele S Dellschaft, Caroline Hoad, et al.
Frontiers in Pharmacology|May 19, 2023
Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-ScoreJochen G Mainz, Carlos Zagoya, Louise Polte, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 23, 2025
Validation of the CFAbd-Score.kid©, a Novel gastrointestinal patient reported outcome measure, specific for children with cystic fibrosisPauline Sadrieh, Lilith Bechinger, Franziska Duckstein, et al.
Frontiers in Pharmacology|June 20, 2022
Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-ScoreJochen G Mainz, Carlos Zagoya, Louise Polte, et al.
American Journal of Respiratory and Critical Care Medicine|April 18, 2013
Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutationJane C Davies, Claire E Wainwright, Gerard J Canny, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 9, 2016
Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trialJochen G Mainz, Ulrike Schumacher, Katja Schädlich, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 21, 2020
Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance ImagingChristabella Ng, Neele S Dellschaft, Caroline L Hoad, et al.
Microbiology Spectrum|March 9, 2023
The Cystic Fibrosis Upper and Lower Airway MetagenomeKatarzyna Pienkowska, Marie-Madlen Pust, Margaux Gessner, et al.
Pageof 8